All News

Watch Dr. Veda N. Giri, from Sidney Kimmel Cancer Center at Thomas Jefferson University, discuss genetic testing and who should get it, during the CURE Educated Patient Prostate Cancer Summit.

Brukinsa, which was approved in September 2021, resulted in better ouctomes for certain patients with with Waldenström macroglobulinemia, according to the ASPEN clinical trial.

Patients who underwent Revlimid, Velcade, and dexamethasone therapy followed by maintenance Revlimid, tended to have better outcomes when they underwent autologous stem cell transplant.

Cancer and its treatments can affect oral health, though when I was diagnosed with breast cancer, the thought of seeing the dentist slipped my mind.

From Tampa Bay Buccaneers quarterback Tom Brady letting children with cancer dye his hair orange to the name of a cancer drug causing controversy at the Scripps National Spelling Bee, here’s what’s happening in the cancer space this week.

Watch Dr. Ganesh Raj, Dr. Andrew Z. Wang, and Bruce Williams, discuss treatment for localized disease, during the CURE Educated Patient Prostate Cancer Summit.

With no approved therapies for NRG-1 cancers, zenocutuzumab offers a promising treatment option for this patient population.

The use of Jakafi plus chemotherapy shows promise in the pre- and post-surgical treatment settings for patients with stage 3 and 4 ovarian cancer, warranting further study of the combination.

One of the most loving things I can do for my family is to purchase life insurance, but my application was turned down, presumably because of my cancer history.

Watch Dr. Andrew Z. Wang, from UT Southwestern Medical Center, discuss approaches to radiation for local disease, during the CURE Educated Patient Prostate Cancer Summit.

After more than two years of follow-up, patients with previously untreated, locally advanced stage 3 non–small cell lung cancer continue to derive a benefit from treatment with Keytruda and chemoradiation.

One-hundred percent of patients with stage 2/3 mismatch repair-deficient rectal cancer had their disease disappear after treatment with Jermperli, though more research and longer follow-up is needed.

Getting other medical opinions for my cancer diagnosis not only saved my life but also taught me self-care.

Although ineffective in patients with non-small cell lung cancer and brain metastases at diagnosis, treatment with Exkivity may benefit patients with EGFR exon 20 insertion-positive metastatic disease.

Watch Dr. Ganesh V. Raj, from UT Southwestern Medical Center, discuss surgery for localized disease, during the CURE Educated Patient Prostate Cancer Summit.

The use of the chemotherapy ifosfamide was associated with small improvements in survival outcomes in a group of patients with relapsed/refractory Ewing sarcoma, a rare type of bone or soft tissue cancer.

Actress and comedian Jessica St. Clair and her husband, Dan O’Brien, share their roles of partner and parent, but also patient and cancer caregiver, as their roles were reversed in the blink of an eye.

I was approached with the opportunity to ghostwrite for an author who was writing about his cancer journey. I’m still baffled by the timing, but that experience shifted into my eventual cancer journey.

The findings of the study show that Enhertu should be a new standard of care for patients with HER2-low metastatic breast cancer, according to an expert at Memorial Sloan Kettering Cancer Center.

Patients with multiple myeloma were more likely to have no traceable amounts of disease left when Darzalex was added to a treatment regimen of Revlimid, Velcade and dexamethasone.

Survival outcomes and side effect rates were similar in patients with extensive-stage small cell lung cancer who did and did not have tiragolumab added to their treatment regimen of Tecentriq and chemotherapy.

Despite similar responses to treatment, patients with previously treated non-small cell lung cancer derived a better overall survival benefit from treatment with Keytruda combined with Cyramza than the usage of standard-of-care therapies.

Having someone beside you to accompany you during doctor's visits to take notes or having someone to help you find the right specialist or even to just help research what treatment options are available can be incredibly helpful.

At a follow-up of more than two years, treatment with a novel drug produced meaningful results in a group of patients with HER3-expressing metastatic breast cancer or metastatic triple-negative breast cancer.

The investigational agent SOT101 was safe and tolerable when given alone and in combination with Keytruda for patients with solid tumors.

Long-term study results show that outcomes, such as survival and response rates, in patients who have received Calquence-containing treatment regimens continue to outpace outcomes in those who were given Gazyva and chemotherapy.

Treatment with Trodelvy resulted in slight survival improvements, when compared with standard of care chemotherapy regimens, in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Treatment with Lenvima plus Keytruda resulted in a 50% decrease in risk of disease progression or death compared with Sutent in patients with advanced kidney cancer.